Chi-Med gets $18m from Lilly deal
This article was originally published in Scrip
Executive Summary
Hutchison China MediTech, or Chi-Med, has picked up an $18m milestone payment from Lilly, following positive results from the first proof-of-concept study for its colorectal cancer therapy fruquintinib.